Eisai India launches Leqembi for early Alzheimer’s patients at ₹21,682 per vial
Eisai India has launched Leqembi for eligible early-stage Alzheimer’s patients, with local distribution and a post-launch Phase IV real-world study planned. The drug is priced at ₹21,682 per vial amid rising dementia prevalence and access challenges in India.
Eisai India launched Alzheimer’s drug Leqembi for eligible early-stage patients, priced at ₹21,682 per vial. The company will conduct a Phase IV Indian study post-launch and distribute the treatment locally, citing rising dementia incidence and access barriers.
Why this matters
No prior related signals were provided for Eisai India; the Leqembi launch adds an Alzheimer’s treatment access and distribution development to the brand’s signal set.
Retail-brand signals are accelerating, up 95,725% QoQ.